Autoantibodies against Aquaporin-4 (AQP-4) and Myelin-Oligodendrocyte Glycoprotein (MOG) can be used for differential diagnosis.
Autoantibodies against Aquaporin-4 (AQP-4) or Myelin-Oligodendrocyte Glycoprotein (MOG) are detectable in demyelinating diseases of the central nervous system. MOG autoantibodies are mostly found in pediatric patients.
Early differentiation between demyelinisation associated with AQP-4-IgG or MOG-IgG can help decide on therapeutic measures. This is useful with patients suffering from Neuromyelitis optica spectrum disorders (NMOSD) and patients with multiple sclerosis (MS).
More specifically, patients with MOG-IgG tend to have a single or a lower number of disease attacks and usually demonstrate better recovery from the attack. MOG-IgG seropositive patients are usually marked by a better outcome in comparison with AQP4-IgG seropositive patients regardless of the course of the disease.
NMOSD Screen 1:
Differential diagnosis of:
- Multiple sclerosis
- Acute disseminated encephalomyelitis (ADEM)
- AQP-4-seronegative NMSOD